Stonegate Capital Partners has updated its coverage on OS Therapies Inc. (NYSE: OSTX), emphasizing significant regulatory advancements for the company's lead candidate, OST-HER2, in treating recurrent, fully resected, pulmonary metastatic osteosarcoma. The updates mark a transition from early-stage validation toward a defined global approval pathway, with key milestones expected throughout 2026.
The most notable development is the increased regulatory clarity. The European Medicines Agency (EMA) has initiated a rolling review of the OST-HER2 Conditional Marketing Authorization (CMA) dossier, while the EMA and Australia’s Therapeutic Goods Administration (TGA) have aligned on 3-year overall survival as the approvable efficacy endpoint. Additionally, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted Advanced Therapy Medicinal Product (ATMP) designation. These steps, combined with planned FDA and MHRA meetings in the second quarter of 2026, position OST-HER2 for an executable global approval pathway.
Management has also positioned seroconversion biomarker data as supportive surrogate efficacy evidence, shifting the investment debate from early proof-of-concept toward execution across a dense 2026 catalyst calendar. Key upcoming milestones include 2.5-year overall survival (OS) data in mid-second quarter 2026, Phase 3 trial initiation in Australia in the third quarter, 3-year OS data in early fourth quarter, and a potential EMA CMA decision in the fourth quarter.
The survival data are critical catalysts. The mid-2026 2.5-year OS data and early-fourth quarter 3-year OS data will determine whether OS Therapies can complete the EMA CMA submission and sustain accelerated-access momentum. These data points are expected to provide the efficacy evidence needed for regulatory approvals and to support ongoing discussions with health authorities.
Financing and potential Priority Review Voucher (PRV) optionality provide a bridge through the regulatory window. The company raised $5.25 million, and with an expected $4.0 million in non-dilutive funding, it is positioned to support the 2026 catalyst calendar. A potential PRV remains a meaningful approval-contingent valuation lever, with the latest public transaction valued at $205 million.
For investors, the regulatory clarity and defined catalyst timeline reduce uncertainty around OST-HER2’s path to market. The alignment on survival endpoints with EMA and TGA increases the likelihood of successful submissions, while the rolling review process accelerates the timeline. The dense catalyst calendar in 2026 provides multiple opportunities for value inflection, making OS Therapies a stock to watch in the oncology space.
Full details are available in the original announcement from Stonegate Capital Partners at Stonegate Inc.
